

TREATING LUNG CANCER IN A RAPIDLY EVOLVING LANDSCAPE

Sunday, 21 October, 13:00 – 14:30

HALL B3-ROOM 20, MESSE MUNICH
MUNICH, GERMANY

At this symposium, an international faculty of experts will discuss treatment sequencing in *EGFR* mutation-positive NSCLC and the efficacy of EGFR TKIs in patients with uncommon mutations. Treatment considerations for second-line and beyond in non-mutated, non-squamous NSCLC will also be discussed.

13:00 – 13:10

Meeting welcome and introductions

James Yang

13:10 – 13:30

Sequencing in *EGFR*-mutated NSCLC: does order matter?

Maximilian Hochmair

13:30 – 13:45

Efficacy of EGFR TKIs in patients with uncommon mutations

Edward Kim

13:45 – 14:00

Panel discussion: treatment considerations for *EGFR*-mutated NSCLC

All Faculty; moderated by James Yang

14:00 – 14:15

Treating second-line and beyond in non-mutated, non-squamous NSCLC: now and tomorrow

Sanjay Popat

14:15 – 14:25

Panel discussion: treatment considerations for non-mutated, non-squamous NSCLC

All Faculty; moderated by James Yang

14:25 – 14:30

Meeting close

James Yang

